
Russian Chemical Bulletin p. 682 - 688 (1995)
Update date:2022-08-11
Topics:
Pleshakov, V. G.
Akimov, V. M.
Nava, E. Huipe
Lindeman, S. V.
Struchkov, Yu. T.
et al.
Based on thermogravimetric characteristics first obtained for the model 6H-indeno<1,2-b>quinoline, the scheme of thermal conversions of this compound in the temperature range 20-700 deg C has been proposed, and the limit of its thermal stability (ca. 300 deg C) has been determined.This temperature is recommended as the optimum for synthesizing fused benzoaza(diaza)fluorenes.Based on the results of X-ray structural analysis, the molecules of the studied indenoquinoline form centrosymmetric pairs, which are arranged in (110) layers.The molecules are orientationally disordered self-association of these molecules is similar to the ?-? association of fused heterocyclic systems with ?-excessive and ?-deficient fragments.It has been suggested that interferon-inducing and antitumor compounds with an annelated indenyl fragment have a common mechanism of action according to the intercalation model of stacking structures. - Key words: CH-acids; 6H-indeno<1,2-b>quinoline, heterogeneous catalytic dehydrogenation, thermogravimetric and X-ray structural analysis; interferon-inducing and antitumor intercalators; topological factor; stacking structures.
View More
Sichuan Highlight Fine Chemicals Co., Ltd.
Contact:+86-28-8525 1605
Address:A5-102 Airport base,388 West Airport Huang He Zhong Lu,2 Section
Weihao Chemtech (ChangZhou) Co., Ltd.(expird)
Contact:051989185693
Address:NO 217 huangshan Rd ,Changzhou
SHANGHAI T&W PHARMACEUTICAL CO., LTD.
website:http://www.trustwe.com
Contact:+86-21-61551413
Address:601, No. 1, 2277 Nong, Zu Chongzhi Road, Zhangjiang Hightech. Park, Pudong
Hangzhou Yingshanhua Pigment Chemicals Co.,Ltd.
Contact:+86-0150-58101658
Address:Nanyang Economic DevelopmentZong,Xiaoshan,Hangzhou,China
NINGBO YINLIANG FOREIGN TRADE CO., LTD.
Contact:+86-574-87834016 / 87898057
Address:23F NO.666JINYU ROAD,YINGZHOU DISTRICT,NINGBO.CHINA
Doi:10.1016/j.tet.2005.06.120
(2005)Doi:10.1021/j100342a039
(1989)Doi:10.1007/s10600-005-0159-y
(2005)Doi:10.1016/j.ijpharm.2010.05.035
(2010)Doi:10.1007/BF00471245
()Doi:10.1021/j100380a004
(1990)